News | November 07, 2025
Philips reiterates FY25 outlook following steady Q3 performance
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
_256_384.jpg)
The transaction is expected to be completed within one month from the signing of the definitive agreements.
_256_384.jpg)
Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Subscribe To Our Newsletter & Stay Updated
